Astragaloside IV, an active component isolated from Astragalus membranaceus, can protect the myocardium against ischemia/reperfusion injury and Inhibits HAdV-3 replication and reduces HAdV-3-induced apoptosis [1].
Astragaloside IV (10-160μg/ml; 48h) dose-dependently decreased lncRNA-ATB expression in SMMC-7721 cells. Astragaloside IV (160μg/ml; 48h) down-regulated lncRNA-ATB expression and inhibited HCC cell migration[2].Astragaloside IV (40-100μg/ml; 24h) inhibited the viability and invasive potential of MDA-MB-231 breast cancer cells, suppressed the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulated matrix metalloproteases (MMP)-2 and -9[3].
Astragaloside IV (12.5, 25, and 50mg/kg; po; 7days) attenuated the neurological deficit in rats with ischemica-reperfusion injury, and reduced cerebral infarction and neuronal apoptosis. Astragaloside IV inhibited the mRNA upregulation of Fas, FasL, Caspase-8, and Bax/Bcl-2[4].After the intervention of Astragaloside IV (20, 40, 80mg/kg; po; 12weeks) the expressions of pSmad3C, pNrf2, HO-1, and NQO1 were increased, and the expressions of TGF-β1, pSmad3L, pSmad2C, pSmad2L, PAI-1 were inhibited[5].
References:
[1]. Shang L, Qu Z, Sun L, Wang Y, Liu F, Wang S, Gao H, Jiang F. Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro. J Pharm Pharmacol. 2011 May;63(5):688-94.
[2]. Li Y, Ye Y, Chen H. Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB. Biomed Pharmacother. 2018 Mar;99:134-141.
[3]. Jiang K, Lu Q, Li Q, Ji Y, Chen W, Xue X. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2017 Jan;42:195-202.
[4]. Yin F, Zhou H, Fang Y, Li C, He Y, Yu L, Wan H, Yang J. Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway. J Ethnopharmacol. 2020 Feb 10;248:112319.
[5]. Zhang C, Li L, Hou S, Shi Z, Xu W, Wang Q, He Y, Gong Y, Fang Z, Yang Y. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways. J Ethnopharmacol. 2021 Oct 28;279:114350.
Astragaloside IV是黄芪中提取的一种有效成分，可减轻心肌缺血/再灌注损伤，抑制HAdV-3复制，减少HAdV-3诱导的细胞凋亡[1]。
Astragaloside IV （10-160 μg/ml；48h）呈剂量依赖性地降低SMMC-7721细胞中lncRNA-ATB的表达。Astragaloside IV （160 μg/ml；48h）下调lncRNA-ATB表达抑制肝癌细胞迁移[2]。Astragaloside IV （40-100μg/ml；24h）抑制MDA-MB-231乳腺癌细胞的活力和侵袭潜能，抑制丝裂原活化蛋白激酶(MAPK)家族成员ERK1/2和JNK的活化，下调基质金属蛋白酶(MMP)-2和-9的表达[3]。
Astragaloside IV （12.5、25和50 mg/kg；7 days）可减轻缺血再灌注损伤大鼠的神经功能缺损，减少脑梗死和神经元凋亡。Astragaloside IV抑制Fas、FasL、Caspase-8、Bax/Bcl-2mRNA的上调[4]。Astragaloside IV （20、40、80mg/kg；po；12weeks）干预后，pSmad3C、pNrf2、HO-1、NQO1表达增加，TGF-β1、pSmad3L、pSmad2C、pSmad2L、PAI-1表达抑制[5]。